Avaliação clínica, imuno-histoquímica e genética dos pacientes com câncer de mama

Abstract

There are many or severe risk factors can act as promoters of lhe development of breast câncer The analyses of such factors, along with epidemiologic, clinicai, immunohistochemical and genetic data and their inflnences on global survival and disease-free survival have been assessed in the present study. Patients and methods One hundred-seventy-seven patients with breast câncer from the Oncology Center at the Federal University of Uberlândia were studied from January to December 2001. Epidemiological data, risk factors, clinical and laboratory evaluation, treatment response and toxicity, multi-drug resistance gene polymorphism and hormone receptors were statistically evaluated, establishing a significance level of 0.05, basically using Student's t-test, Chi-square and Log Rank. Results No statistically significant differences in survival were observed that involved analyzes of: race, age at menarche, menstrual period, obstetric history, hormone replacement use, family history, body mass index, alcohol and cigarette use, tumor location, MDR 1 gene polymorphism, C-erb-B2 positivity, Ki-67 positivity index and degree of toxicity. There was a statistically significant difference in survival according to the number of lymph nodes dissected and compromised by the neoplasia, diagnosis age, time of symptomatology, type of surgery performed, pathological staging, chemotherapy or hormone therapy regimen, estrogen and progesterone receptor positivity and p53 expression. . Conclusions The various risk factors and promoters of breast cancer showed no interference in the survival of the patients studied. However, in the survival analysis, it was shown that numerous other variables can improve or worsen overall survival and disease-free survival by influencing treatment indication.